NCT07008664View on ClinicalTrials.gov

Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Lung Cancer

RecruitingOBSERVATIONAL
Enrollment

750

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

April 30, 2031

Study Completion Date

April 30, 2032

Conditions
Lung CancerLung Cancer ScreeningHealthy Volunteers (HV)Unhealthy Volunteers
Interventions
OTHER

Epigenetic Signature Assay

Up to 15 ml of blood will be collected from each patient at various time points throughout their 5 years of participation. DNA extraction, bisulfite conversion and analysis of epigenetic markers through PCR or next-generation sequencing will be performed. An epigenetic signature assay will then be identified.

Trial Locations (1)

21061

RECRUITING

University of Maryland Baltimore Washington Medical Center, Glen Burnie

All Listed Sponsors
collaborator

EPOCH Epigenetics, Inc

UNKNOWN

lead

University of Maryland, Baltimore

OTHER